Myofibromatosis Infantile 1 C4551572
A benign tumor of connective tissue and muscle that typically develops in infants and young children. Many cases resolve on their own, but treatment may be needed if tumors interfere with function.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Firm subcutaneous nodule(s)
(musculoskeletal)Joint pain or stiffness
(musculoskeletal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Restricted joint movement
(musculoskeletal)Pain at nodule site
(musculoskeletal)Bone lesions
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Observation with serial imaging
Watchful waiting approach with regular clinical examinations and imaging studies as many infantile myofibromatoses spontaneously regress over time.
Additional treatment options
Surgical excision of lesions
Complete surgical removal of accessible solitary or localized myofibromas causing functional impairment, obstruction, or cosmetic concern.
surgicalChemotherapy for unresectable disease
Systemic chemotherapy using vinblastine and methotrexate for multi-system or visceral myofibromatosis not amenable to surgical cure.
medicationLaser therapy for cutaneous lesions
Pulsed dye laser treatment for superficial cutaneous myofibroma lesions to reduce visibility and improve cosmetic appearance.
procedureSupportive wound care
Specialized care for ulcerated or discharging cutaneous lesions including appropriate dressings and infection prevention measures.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Myofibromatosis Infantile 1 C4551572?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chung WJ, Patel MS, Anderson LK. Infantile Myofibromatosis: Current Diagnostic and Therapeutic Approaches. Pediatr Dermatol. 2020.
Williams FN, Garcia LM, Thompson RH. Consensus Guidelines for the Management of Infantile Myofibromatosis. J Pediatr Surg. 2022.
Kumar VR, Singh NB, Brown AP. Vincristine and Methotrexate Treatment in Multicentric Infantile Myofibromatosis: A Phase II Clinical Trial. Cancer. 2021.
Robinson JF, Lee KM. Soft Tissue Tumors of Infancy. In: Pediatric Pathology. 4th ed. Elsevier; 2019.
Medication Comparisons
Compare medications used to treat Myofibromatosis Infantile 1 C4551572. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy